Overview
Protects the tiny power plants inside your cells from age-related damage.
FDA-approved (as Forzinity) for one rare disease; people use it off-label for energy and longevity.
What It Does
Mitochondria-targeted tetrapeptide, FDA accelerated approval as FORZINITY® for Barth syndrome (Sep 19, 2025), the first FDA-approved mitochondria-targeted drug (commercially available Dec 2025).
Concentrates in the inner mitochondrial membrane via cardiolipin binding.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 5 mg | + 0.25 mL | 20 mg/mL |
| 10 mg | + 0.50 mL | 20 mg/mL |
| 50 mg | + 2.5 mL | 20 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Weeks 1– | Daily AM | 2.5 | Tolerance ramp. Start low; assess GI and injection-site response. |
| Weeks 3– | Daily AM | 5 mg | Standard longevity-community working dose; some protocols run up to 10 mg/day. FDA Forzinity is 40 mg/day SC for Barth |
| Off | 4–8 weeks | – | Consolidation. Sequences naturally into a MOTS-c cycle. |
8–12 wks on / 4 wks off (longevity range); Forzinity is daily-continuous for Barth.
Daily AM or anytime, consistency more important than timing. Other indications (dry AMD / geographic atrophy, primary mitochondrial myopathy) remain trial-stage; not approved.
Unisex mitochondrial peptide, same protocol for men and women, no cycle effect. FDA-approved (Forzinity) use is disease-specific; avoid in pregnancy.
Handling & Stacking
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F.
- Best used within 28 days.
- There's no reliable community potency figure for SS-31, so treat the reconstituted vial as sterility-limited at ~28–30 days refrigerated at 36–46°F and dark; it's a small robust tetrapeptide with no published data, so that's a best-guess default, not a measured window.
- Energy and exercise-capacity improvement at 4–8 weeks.
- Injection-site redness expected.
- First step of the mitochondrial longevity sequence: SS-31 → MOTS-c.
- Supply math 5mg → 77 vials | 10mg → 39 | 50mg → 8 vials (12-wk @ 5 mg × 7/wk)
Safety & Patient Education
- FDA-approved (Forzinity) for Barth syndrome only; longevity use is off-label.
- The community 5 mg is 1/8 of the 40 mg/day label and about 1/8 of the ~0.5 mg/kg behind every positive human result, so treat it as an affordability-and-tolerability dose, not a validated one.
- Every human trial dosed daily; no trial has tested less-than-daily.
- CMP/BMP renal function (baseline + mid-cycle; it's renally cleared and concentrates in the kidney); otherwise very well tolerated in trials, injection-site reactions are the main thing to watch., Out of range?
- A rising creatinine or falling eGFR = kidney strain (hydrate, hold the dose); no glucose signal is expected on SS-31.
- A rash or hives (not just local redness) warrants a CBC with differential and stopping, the label lists hypersensitivity.
- Persistent injection-site reactions (beyond 7 days); headache not resolving.
- Stop and seek care for hives or rash away from the site, facial swelling, or breathing symptoms, that's hypersensitivity, not an ISR.
- A site that is hot, spreading, and worsening past 48 h may be infection.
- Aseptic technique; single-use sterile needle each injection; never share vials/needles.
- Sharps in an FDA-cleared container.
- Maintain cold chain; mark first-puncture date; inspect every vial before use.
- Rotate injection sites.
